Investigating how glucocorticoids and immune cells help recover lung function after injury.
The effect of endogenous and exogenous glucocorticoids acting through regulatory T cells on resolution of ALI and the contribution of host genetic variability.
This study is looking at how special immune cells help heal the lungs after serious conditions like ARDS and pneumonia, and it will see how a common steroid medication affects these cells to find out why some people recover better than others, with the hope of creating more tailored treatments for lung injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11050204 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain immune cells, known as regulatory T cells, contribute to the healing process of the lungs following acute respiratory distress syndrome (ARDS) and pneumonia. The study will explore the effects of glucocorticoids, a type of steroid medication, on these immune cells and how they may influence recovery. By examining the genetic variability among patients, the research aims to identify why some individuals respond better to glucocorticoid treatment than others. This could lead to more personalized and effective therapies for patients suffering from lung injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults diagnosed with acute respiratory distress syndrome (ARDS) or pneumonia.
Not a fit: Patients with chronic lung diseases or those who do not have acute lung injuries may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with acute lung injuries, enhancing their recovery and overall lung function.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune cells in lung recovery, but this specific approach to glucocorticoid effects on Tregs is relatively novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Mock, Jason Robert — Univ of North Carolina Chapel Hill
- Study coordinator: Mock, Jason Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.